top of page

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

blonca9
Apr 15
1 min read

CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A commercial stage company that already receives income from two therapies (YUPELRI and TRELEGY), Theravance Biopharma's future direction and focus will be determined by the outcome of this key trial.

Recent Posts

See All

Dianthus Therapeutics made waves in September when it announced data from its lead program claseprubart in generalized Myasthenia Gravis - CEO Marino Garcia walks us through the program and data

OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate